• Epoxomicin: Advanced Proteasome Inhibitor for Pathway Resear

  2026-07-14

  Epoxomicin distinguishes itself as a gold-standard, irreversible proteasome inhibitor, ideal for dissecting the ubiquitin-proteasome pathway in cellular and disease models. This guide delivers hands-on workflows, troubleshooting strategies, and insights from recent viral immunity research to optimize your experimental outcomes.

• Rapakinin-Induced Vasorelaxation via PGI2–IP and CCK1 Pathwa

  2026-07-14

  The referenced study establishes rapakinin, a peptide from rapeseed protein, as a vasorelaxant that lowers blood pressure in hypertensive rats by activating the prostaglandin I2 (PGI2)–IP receptor pathway, followed by the cholecystokinin (CCK1) receptor. This work clarifies a novel, nitric oxide–independent mechanism for vascular relaxation, providing new insights for antihypertensive research and potential gut-cardiovascular therapeutic intersections.

• Lovastatin: Mechanism, Benchmarks, and Research Integration

  2026-07-13

  Lovastatin is a potent HMG-CoA reductase inhibitor that blocks cholesterol biosynthesis at nanomolar concentrations. It induces apoptosis in fibroblasts and cancer cells, with measurable effects on proliferation and macrophage efferocytosis. This article details its mechanism, evidence, and key workflow parameters for advanced research.

• CA-074 Me: Advancing Lysosomal Cathepsin B Inhibition in Nec

  2026-07-13

  This article explores how the selective cathepsin B inhibitor CA-074 Me unlocks mechanistic insights into lysosomal membrane permeabilization and necroptosis. Integrating new findings on MLKL-driven cell death, it offers translational researchers strategic guidance for experimental design and therapeutic exploration, with actionable protocol parameters and a forward-looking perspective on inflammation research.

• GANT61: Unlocking GLI2-Driven Immune Evasion for Translation

  2026-07-12

  Explore how GANT61, a potent GLI inhibitor, enables in-depth studies of GLI2-mediated tumor immune evasion and resistance mechanisms in cancer research. This article reveals overlooked assay strategies and translational implications, uniquely bridging molecular inhibition to immunotherapy outcomes.

• hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate PK

  2026-07-10

  This study establishes a direct, efficient protocol for generating human induced pluripotent stem cell-derived intestinal organoids, enabling advanced in vitro pharmacokinetic studies. The model demonstrates functional drug-metabolizing enzyme activity, supporting its application in evaluating CYP2C19 substrates and improving translational drug metabolism research.

• GW4064: Non-Steroidal FXR Agonist for Metabolic Pathway Diss

  2026-07-09

  GW4064 empowers researchers to interrogate FXR-driven regulation of lipid, bile acid, and fibrotic pathways with unprecedented precision. By bridging recent breakthroughs in FXR/TLR4/ferroptosis axis research, this guide delivers actionable workflow enhancements and troubleshooting tactics for leveraging APExBIO’s GW4064 in advanced metabolic studies.

• Distinct PARP1 Apoptotic Pathways Revealed During RSL3-Induc

  2026-07-09

  This study uncovers how RSL3, a ferroptosis inducer, orchestrates apoptosis through dual mechanisms involving PARP1: caspase-3-dependent cleavage and translation suppression via m6A modification inhibition. These findings clarify the crosstalk between ferroptosis and apoptosis and provide insight into overcoming PARP inhibitor resistance.

• Ibuprofen in Translational Oncology: Mechanistic Depth and S

  2026-07-08

  This thought-leadership article synthesizes mechanistic insights into Ibuprofen’s dual COX inhibition, explores its anti-proliferative role in colon carcinoma, and delivers strategic guidance for translational researchers. Integrating evidence from foundational studies and current best practices—including protein binding, pharmacokinetic nuances, and assay optimization—this piece connects APExBIO’s Ibuprofen with the evolving landscape of precision cancer research, while distinguishing itself through advanced integrative discussion and actionable recommendations.

• Advances in Plant Protein Secretion: Protocols and Pathway I

  2026-07-08

  This reference volume provides an up-to-date, protocol-focused overview of plant protein secretion mechanisms, distinguishing conventional and unconventional pathways with clear experimental guidance. By compiling reproducible, stepwise methods and troubleshooting advice, the book enables researchers to dissect plant secretory systems at a level of rigor previously reserved for yeast and mammalian models.

• Annexin V-Cy5 Apoptosis Kit: Precision Tools for Microglial

  2026-07-07

  Discover how the Annexin V-Cy5 Apoptosis Kit empowers nuanced, quantitative apoptosis detection in microglial stress models. This article provides in-depth analysis, bridging primary research findings with practical assay optimization for advanced neuroimmune studies.

• Cucurbitacin I (JSI-124): Mechanistic Depth and Advanced Can

  2026-07-07

  Explore how Cucurbitacin I enables precise STAT3 pathway inhibition and advanced cancer research, with in-depth analysis of assay design and translational impact. This article offers distinct insights into Cucurbitacin I's mechanistic selectivity, cross-model utility, and practical protocol strategies.

• Doxorubicin Hydrochloride: Molecular Mechanisms and rRNA-Dri

  2026-07-06

  Explore the unique molecular mechanisms of Doxorubicin hydrochloride (Adriamycin HCl) and how emerging insights into rRNA architecture are reshaping assay design in cancer chemotherapy research. This article delivers advanced scientific guidance distinct from conventional overviews.

• Olaparib (AZD2281): Breakthroughs in DNA Replication Stress

  2026-07-06

  Explore how Olaparib (AZD2281) enables advanced research into DNA replication stress and nascent strand maturation, with new protocol insights. This article reveals unique mechanistic findings and practical guidance for BRCA-associated cancer studies.

• GANT61 GLI Inhibitor: Protocols for Tumor Suppression

  2026-07-05

  GANT61 empowers cancer researchers to dissect and disrupt the Hedgehog-GLI axis, enabling robust GLI-mediated transcription inhibition and tumor growth suppression. This article delivers workflow enhancements, troubleshooting solutions, and practical translation of cutting-edge immunotherapy resistance research. Leverage APExBIO’s GANT61 to optimize your Hedgehog pathway experiments with precision.

15728 records 1/1049 page Next 12345 下5页 Last page